Unmet challenges in immune-mediated hepatobiliary diseases.
about
Adaptive immunity in the liverQuantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis.Treatment of cholestatic fibrosis by altering gene expression of Cthrc1: Implications for autoimmune and non-autoimmune liver disease.Deletion of Galectin-3 Enhances Xenobiotic Induced Murine Primary Biliary Cholangitis by Facilitating Apoptosis of BECs and Release of Autoantigens.Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary CholangitisProposed therapies in primary biliary cholangitis.Dysregulation of peritoneal cavity B1a cells and murine primary biliary cholangitis.Epigenetics and Primary Biliary Cirrhosis: a Comprehensive Review and Implications for Autoimmunity.Obeticholic acid for the treatment of primary biliary cirrhosis.The functional characteristics CCNI modulation of myeloid- derived suppressor cells in liver inflammation.The Management of Autoimmune Hepatitis Patients with Decompensated Cirrhosis: Real-World Experience and a Comprehensive Review.Primary Biliary Cholangitis Associated with Skin Disorders: A Case Report and Review of the Literature.Trichloroethylene Exposure Reduces Liver Injury in a Mouse Model of Primary Biliary Cholangitis.Endogenous interleukin-22 protects against inflammatory bowel disease but not autoimmune cholangitis in dominant negative form of transforming growth factor beta receptor type II mice.The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis.New developments in the treatment of primary biliary cholangitis - role of obeticholic acid.Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.
P2860
Q26753195-0EEE036A-CCA4-4230-BCE8-4378F37D1BD8Q36134061-322677AD-1CE6-4CED-8EF4-662DDDB6550AQ36279532-8E83563D-83C1-4254-856F-48BF5EAEF5EDQ36708065-F3743415-901D-4E07-B2A6-58A1F48F36A0Q36914749-D98B32F3-5488-476B-ACC5-4D3A46BE1DD7Q37072380-C2EF8E6B-FFB0-4F33-9150-B49FB6302E31Q37317145-D975BF62-FA9E-4C39-8F9C-86ADF83AC87DQ38565478-1C52212B-9068-4179-A060-C8865BE4EB88Q38628470-22C42C52-E745-4D11-8AF1-1666B32FB338Q38640611-9A713A4D-1881-402E-B972-8E24FFF805BCQ38925324-99CEDE3D-B2D8-4588-A28E-ADAFA172736CQ38998320-EB3175B9-420C-462E-8517-99DCA22EF2E5Q39003378-6C9DEEA4-DBA2-466D-BBC7-92FAFF16D1CEQ39792098-99F4C3F7-F234-43B1-ABBE-261F9AB97ACDQ41303819-34C05037-E6D6-4B5B-BB0D-5CDD6C6FD063Q41531249-D70ED448-0210-4377-8ACC-69900AC7843EQ46194973-E4AC1A01-34C3-40EF-B891-6CAAEE795912Q46813053-1D2950F5-9EC1-4948-84AC-3326CA10BF51
P2860
Unmet challenges in immune-mediated hepatobiliary diseases.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Unmet challenges in immune-mediated hepatobiliary diseases.
@en
Unmet challenges in immune-mediated hepatobiliary diseases.
@nl
type
label
Unmet challenges in immune-mediated hepatobiliary diseases.
@en
Unmet challenges in immune-mediated hepatobiliary diseases.
@nl
prefLabel
Unmet challenges in immune-mediated hepatobiliary diseases.
@en
Unmet challenges in immune-mediated hepatobiliary diseases.
@nl
P2860
P1476
Unmet challenges in immune-mediated hepatobiliary diseases.
@en
P2093
Ulrich Beuers
P2860
P2888
P304
P356
10.1007/S12016-015-8484-9
P577
2015-06-01T00:00:00Z